Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF. Methods: This multicenter retrospective cohort study investigated 338 patients treated with pirfenidone between July 2012 and March 2018. Demographics, pulmonary function, mortality, and pirfenidone-related adverse events were also investigated. Efficacy was analyzed according to pirfenidone dose and disease severity using linear mixed-effects models to assess the annual decline rate of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO). Results: The mean %FVCpredicted and %DLCOpredicted values were 72.6% ± 13.1% and 61.4% ± 17.9%, respectively. The mean duration of pirfenidone treatment was 16.1 ± 9.0 months. In the standard dose (1,800 mg/day) group, the mean %FVCpredicted was −6.56% (95% confidence interval [CI], −9.26 to −3.87) per year before, but −4.43% (95% CI, −5.87 to −3.00) per year after treatment with pirfenidone. In the non-standard lower dose group, the mean %FVCpredicted was −4.96% (95% CI, −6.82 to −3.09) per year before, but −1.79% (95% CI, −2.75 to −0.83) per year after treatment with pirfenidone. The FVC decline rate was significantly reduced, regardless of the Gender-Age-Physiology (GAP) stage. Adverse events and mortality were similar across dose groups; however, they were more frequent in GAP stages II–III than in the stage I group. Conclusions: The effect of pirfenidone on reducing disease progression of IPF persisted even with a consistently lower dose of pirfenidone.
Abstract
Background/Aims: Pirfenidone slows the progression of idiopathic pulmonary fibrosis (IPF). We investigated its efficacy and safety in terms of dose and disease severity in real-world patients with IPF. Methods: This multicenter retrospective cohort study investigated 338 patients treated with pirfenidone between July 2012 and March 2018. Demographics, pulmonary function, mortality, and pirfenidone-related adverse events were also investigated. Efficacy was analyzed according to pirfenidone dose and disease severity using linear mixed-effects models to assess the annual decline rate of forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO). Results: The mean %FVCpredicted and %DLCOpredicted values were 72.6% ± 13.1% and 61.4% ± 17.9%, respectively. The mean duration of pirfenidone treatment was 16.1 ± 9.0 months. In the standard dose (1,800 mg/day) group, the mean %FVCpredicted was −6.56% (95% confidence interval [CI], −9.26 to −3.87) per year before, but −4.43% (95% CI, −5.87 to −3.00) per year after treatment with pirfenidone. In the non-standard lower dose group, the mean %FVCpredicted was −4.96% (95% CI, −6.82 to −3.09) per year before, but −1.79% (95% CI, −2.75 to −0.83) per year after treatment with pirfenidone. The FVC decline rate was significantly reduced, regardless of the Gender-Age-Physiology (GAP) stage. Adverse events and mortality were similar across dose groups; however, they were more frequent in GAP stages II–III than in the stage I group. Conclusions: The effect of pirfenidone on reducing disease progression of IPF persisted even with a consistently lower dose of pirfenidone.
참고문헌 (17)
- Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
- Noble PW, "Pirfenidone in patients with idiopathic pulmonary fibrosis(CAPACITY) : two randomised trials", Lancet, 377, pp.1760~1769 (2011)
- King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
- Okuda R, "Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice", Respir Med, 107, pp.1431~1437 (2013)
- Hughes G, "Real world experiences : pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis", J Clin Med, 5, pp.78~ (2016)
- Harari S, "Efficacy of pirfenidone for idiopathic pulmonary fibrosis : An Italian real life study", Respir Med, 109, pp.904~913 (2015)
- Oltmanns U, "Pirfenidone in idiopathic pulmonary fibrosis : real-life experience from a German tertiary referral center for interstitial lung diseases", Respiration, 88, pp.199~207 (2014)
- Uehara M, "Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia", Respirology, 23, pp.318~324 (2018)
- Taguchi Y, "Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis : extended analysis of phase III trial in Japan", Respir Investig, 53, pp.279~287 (2015)
- Tzouvelekis A, "Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis : a real-world observational study", Pulm Pharmacol Ther, 46, pp.48~53 (2017)
- Yoon HY, "Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis", Respiration, 97, pp.242~251 (2019)
- Ogawa K, "The efficacy and safety of long-term pirfenidone therapy in patients with idiopathic pulmonary fibrosis", Intern Med, 57, pp.2813~2818 (2018)
- Yan YJ, "Real-life experience with pirfenidone in idiopathic pulmonary fibrosis", Zhonghua Jie He He Hu Xi Za Zhi, 41, pp.327~332 (2018)
- Nathan SD, "Dose modification and dose intensity during treatment with pirfenidone : analysis of pooled data from three multinational phase III trials", BMJ Open Respir Res, 5, pp.e000323~ (2018)
- Bando M, "Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis", Intern Med, 55, pp.443~448 (2016)
- Sakayori M, "Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis", Drug Des Devel Ther, 13, pp.2295~2303 (2019)
- Albera C, "Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function", Eur Respir J, 48, pp.843~851 (2016)